TEC: Evidence Based Therapeutics
Therapeutics Education Collaboration
Medication Mythbusters – Home of the Best Science (BS) Medicine Podcast

Episode 290: PREMIUM – Empagliflozin and the EMPA-REG OUTCOME study

In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes. While this is a good finding, upcoming trials of other medications in this class will help put this drug into a context.

Show notes


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type-2 Diabetes

NEJM 2015 DOI: 10.1056/NEJMoa1504720 

Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!


Upcoming Events

Practical Evidence for Informed Practice (PEIP) – October 22-23, 2021

This will be a live-streamed course from Edmonton, AB. Registration Opens August 2021

BS Medicine Podcast

BedMed: The High Blood Pressure Study

This pragmatic trial is now recruiting in BC. Make a difference and get involved with pragmatic trials (www.pragmatictrials.ca)

PEER Tools